Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Randomized, Active-Controlled, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Inventprise's 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults (18 Through 40 Years)

NCT05540028 is registered in ClinicalTrials.gov with Inventprise Inc. as lead sponsor.

NCT NCT05540028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05540028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Randomized, Active-Controlled, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Inventprise's 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults (18 Through 40 Years)
Lead sponsor
Inventprise Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2022
Completion date
July 31, 2023
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal vaccines